Quantib-U BV

Quantib-U is a joint-venture between Quantib and two top academic centres of the Netherlands aimed at developing next level artificial intelligence for precision diagnosis. The collaboration involves assembling large medical datasets and utilising joined medical- and technological expertise to create groundbreaking medical solutions. The joint-venture allows for very rapid prototyping between clinical users, AI- and software- engineers, making it a unique setup. Within days new ideas can be developed and put to practice in a real, multi-centre radiology workflow providing ultrafast feedback. Actively involving clinicians in the development process makes for improved products that are much more likely to get adopted by the end-user and improve the precision diagnosis of more patients worldwide.    

exit per 24 januari 2022

ROTTERDAM, The Netherlands, January 24, 2022 – RadNet, Inc. (NASDAQ: RDNT), a US leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 350 owned and operated outpatient imaging centers, today reported that it has acquired two unrelated Dutch technology companies, Quantib and Aidence. Quantib is a leading radiology artificial intelligence (“AI”) company focusing on clinical solutions for prostate cancer, breast cancer and neurodegeneration. Aidence is a leading radiology AI company focusing on clinical solutions for pulmonary nodule management and lung cancer screening. Read more